Literature DB >> 34216738

Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report.

Jessica Ferguson1, Kanagavel Murugesan2, Niaz Banaei3, Anne Liu4.   

Abstract

We describe the case of a 44-year-old female on Rituximab for treatment of multiple sclerosis with undetectable SARS-CoV-2 IgG specific antibodies eighteen days after second dose of SARS-CoV-2 vaccine. Interferon-gamma release assay testing for SARS-CoV-2 was positive on day nineteen, demonstrating robust T-cell mediated response despite lack of antibody-mediated response.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Year:  2021        PMID： 34216738     DOI： 10.1016/j.ijid.2021.06.054

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN： 1201-9712            Impact factor:   3.623


  7 in total

1.  Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.

Authors:  Giacomo Malipiero; Anna Moratto; Maria Infantino; Pierlanfranco D'Agaro; Elisa Piscianz; Mariangela Manfredi; Valentina Grossi; Enrico Benvenuti; Matteo Bulgaresi; Maurizio Benucci; Danilo Villalta
Journal:  Immunol Res       Date:  2021-08-21       Impact factor: 4.505

2.  Humoral and Cellular Responses to BNT162b2 as a Booster Following Two Doses of ChAdOx1 nCov-19 Determined Using Three SARS-CoV-2 Antibody Assays and an Interferon-Gamma Release Assay: A Prospective Longitudinal Study in Healthcare Workers.

Authors:  Seri Jeong; Nuri Lee; Su Kyung Lee; Eun-Jung Cho; Jungwon Hyun; Min-Jeong Park; Wonkeun Song; Hyun Soo Kim
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

Review 3.  COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus.

Authors:  Parvaneh Hatami; Kamran Balighi; Hamed Nicknam Asl; Zeinab Aryanian
Journal:  Dermatol Ther       Date:  2021-12-01       Impact factor: 2.851

Review 4.  Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis.

Authors:  Grace Y Gombolay; Monideep Dutt; William Tyor
Journal:  Ann Clin Transl Neurol       Date:  2022-07-19       Impact factor: 5.430

5.  Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants.

Authors:  Manon Vogrig; Anne-Emmanuelle Berger; Thomas Bourlet; Louis Waeckel; Alice Haccourt; Alice Chanavat; David Hupin; Frederic Roche; Elisabeth Botelho-Nevers; Bruno Pozzetto; Stéphane Paul
Journal:  J Clin Immunol       Date:  2022-08-25       Impact factor: 8.542

6.  Autoimmune diseases and vaccines against COVID-19. Decision-making in uncertain scenarios.

Authors:  Alberto E Calvo Elías; Lucía Pérez Casado; José Luis Callejas Rubio
Journal:  Med Clin (Engl Ed)       Date:  2022-06-29

7.  B Cell Depletion and SARS-CoV-2 Vaccine Responses in Neuroimmunologic Patients.

Authors:  Stefan Winkler; Judith H Aberle; Selma Tobudic; Barbara Kornek; Fritz Leutmezer; Paulus S Rommer; Maximilian Koblischke; Lisa Schneider; Helmuth Haslacher; Renate Thalhammer; Fritz Zimprich; Gudrun Zulehner; Gabriel Bsteh; Assunta Dal-Bianco; Walter Rinner; Karin Zebenholzer; Isabella Wimmer; Anja Steinmaurer; Marianne Graninger; Margareta Mayer; Kilian Roedl; Thomas Berger
Journal:  Ann Neurol       Date:  2022-02-08       Impact factor: 11.274
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.